The DOI matches its Crossref record; 82 of the 82 references it cites were found in a registry or an index.
A guide to manufacturing CAR T cell therapies
Abstract
In recent years, chimeric antigen receptor (CAR) modified T cells have been used as a treatment for haematological malignancies in several phase I and II trials and with Kymriah of Novartis and Yescarta of KITE Pharma, the first CAR T cell therapy products have been approved. Promising clinical outcomes have yet been tempered by the fact that many therapies may be prohibitively expensive to manufacture. The process is not yet defined, far from being standardised and often requires extensive manual handling steps. For academia, big pharma and contract manufacturers it is difficult to obtain an overview over the process strategies and their respective advantages and disadvantages. This review details current production processes being used for CAR T cells with a particular focus on efficacy, reproducibility, manufacturing costs and release testing. By undertaking a systematic analysis of the manufacture of CAR T cells from reported clinical trial data to date, we have been able to quantify recent trends and track the uptake of new process technology. Delivering new processing options will be key to the success of the CAR-T cells ensuring that excessive manufacturing costs do not disrupt the delivery of exciting new therapies to the wide possible patient cohort.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407222 · Cited by 5,413
Wherry, E. J. (2011) · Nature Immunology · doi:10.1038/ni.2035 · Cited by 4,062
Chimeric antigen receptor–modified T cells in chronic lymphoid leukemia
Porter, D. L., Levine, B. L., Kalos, M., Bagg, A., & June, C. H. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103849 · Cited by 3,565
Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
Grupp, S. A., Kalos, M., Barrett, D., Aplenc, R., Porter, D. L., Rheingold, S. R., Teachey, D. T., Chew, A., Hauck, B., Wright, J. F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215134 · Cited by 3,509
Molecular mechanisms of T cell co-stimulation and co-inhibition
Chen, L., & Flies, D. B. (2013) · Nature Reviews Immunology · doi:10.1038/nri3405 · Cited by 3,114
Lee, D. W., Kochenderfer, J. N., Stetler-Stevenson, M., Cui, Y. K., Delbrook, C., Feldman, S. A., Fry, T. J., Orentas, R., Sabatino, M., Shah, N. N., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61403-3 · Cited by 2,898
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
Davila, M. L., Riviere, I., Wang, X., Bartido, S., Park, J., Curran, K., Chung, S. S., Stefanski, J., Borquez-Ojeda, O., Olszewska, M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008226 · Cited by 2,476
Kalos, M., Levine, B. L., Porter, D. L., Katz, S., Grupp, S. A., Bagg, A., & June, C. H. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002842 · Cited by 2,388
CD19 CAR–T cells of defined CD4+:CD8+ composition in adult B cell ALL patients
Turtle, C. J., Hanafi, L.-A., Berger, C., Gooley, T. A., Cherian, S., Hudecek, M., Sommermeyer, D., Melville, K., Pender, B., Budiarto, T. M., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci85309 · Cited by 2,112
Brentjens, R. J., Davila, M. L., Riviere, I., Park, J., Wang, X., Cowell, L. G., Bartido, S., Stefanski, J., Taylor, C., Olszewska, M., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005930 · Cited by 2,063
A human memory T cell subset with stem cell–like properties
Gattinoni, L., Lugli, E., Ji, Y., Pos, Z., Paulos, C. M., Quigley, M. F., Almeida, J. R., Gostick, E., Yu, Z., Carpenito, C., et al. (2011) · Nature Medicine · doi:10.1038/nm.2446 · Cited by 1,974 · cited 1×
“2011 [21] suggest that the use of IL-2, especially in excessive concentrations, can lead to an exhausted T cell product that has entered into stages of dysfunction, displaying poor effector function and quickly approaching apoptosis [22].”
BackgroundPorter, D. L., Hwang, W.-T., Frey, N. V., Lacey, S. F., Shaw, P. A., Loren, A. W., Bagg, A., Marcucci, K. T., Shen, A., Gonzalez, V., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aac5415 · Cited by 1,729
Kochenderfer, J. N., Dudley, M. E., Kassim, S. H., Somerville, R. P. T., Carpenter, R. O., Stetler-Stevenson, M., Yang, J. C., Phan, G. Q., Hughes, M. S., Sherry, R. M., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.2025 · Cited by 1,595
Gross, G., Waks, T., & Eshhar, Z. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.24.10024 · Cited by 1,590
The Basic Principles of Chimeric Antigen Receptor Design
Sadelain, M., Brentjens, R., & Rivière, I. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0548 · Cited by 1,535
Inducible Apoptosis as a Safety Switch for Adoptive Cell Therapy
Di Stasi, A., Tey, S.-K., Dotti, G., Fujita, Y., Kennedy-Nasser, A., Martinez, C., Straathof, K., Liu, E., Durett, A. G., Grilley, B., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1106152 · Cited by 1,512
Kochenderfer, J. N., Dudley, M. E., Feldman, S. A., Wilson, W. H., Spaner, D. E., Maric, I., Stetler-Stevenson, M., Phan, G. Q., Hughes, M. S., Sherry, R. M., et al. (2012) · Blood · doi:10.1182/blood-2011-10-384388 · Cited by 1,440
Ivics, Z., Hackett, P. B., Plasterk, R. H., & Izsvák, Z. (1997) · Cell · doi:10.1016/s0092-8674(00)80436-5 · Cited by 1,430
Johnson, L. A., Morgan, R. A., Dudley, M. E., Cassard, L., Yang, J. C., Hughes, M. S., Kammula, U. S., Royal, R. E., Sherry, R. M., Wunderlich, J. R., et al. (2009) · Blood · doi:10.1182/blood-2009-03-211714 · Cited by 1,418
Kochenderfer, J. N., Wilson, W. H., Janik, J. E., Dudley, M. E., Stetler-Stevenson, M., Feldman, S. A., Maric, I., Raffeld, M., Nathan, D.-A. N., Lanier, B. J., et al. (2010) · Blood · doi:10.1182/blood-2010-04-281931 · Cited by 1,337
Brentjens, R. J., Rivière, I., Park, J. H., Davila, M. L., Wang, X., Stefanski, J., Taylor, C., Yeh, R., Bartido, S., Borquez-Ojeda, O., et al. (2011) · Blood · doi:10.1182/blood-2011-04-348540 · Cited by 1,286
Pule, M. A., Savoldo, B., Myers, G. D., Rossig, C., Russell, H. V., Dotti, G., Huls, M. H., Liu, E., Gee, A. P., Mei, Z., et al. (2008) · Nature Medicine · doi:10.1038/nm.1882 · Cited by 1,195
Louis, C. U., Savoldo, B., Dotti, G., Pule, M., Yvon, E., Myers, G. D., Rossig, C., Russell, H. V., Diouf, O., Liu, E., et al. (2011) · Blood · doi:10.1182/blood-2011-05-354449 · Cited by 1,163
Gardner, R. A., Finney, O., Annesley, C., Brakke, H., Summers, C., Leger, K., Bleakley, M., Brown, C., Mgebroff, S., Kelly-Spratt, K. S., et al. (2017) · Blood · doi:10.1182/blood-2017-02-769208 · Cited by 1,121
Engineered T cells: the promise and challenges of cancer immunotherapy
Fesnak, A. D., June, C. H., & Levine, B. L. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.97 · Cited by 1,074
Savoldo, B., Ramos, C. A., Liu, E., Mims, M. P., Keating, M. J., Carrum, G., Kamble, R. T., Bollard, C. M., Gee, A. P., Mei, Z., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci46110 · Cited by 1,023
Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells
Qasim, W., Zhan, H., Samarasinghe, S., Adams, S., Amrolia, P., Stafford, S., Butler, K., Rivat, C., Wright, G., Somana, K., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aaj2013 · Cited by 902
Self-citationToxicity and management in CAR T-cell therapy
Bonifant, C. L., Jackson, H. J., Brentjens, R. J., & Curran, K. J. (2016) · Molecular Therapy - Oncolytics · doi:10.1038/mto.2016.11 · Cited by 885
Beatty, G. L., Haas, A. R., Maus, M. V., Torigian, D. A., Soulen, M. C., Plesa, G., Chew, A., Zhao, Y., Levine, B. L., Albelda, S. M., et al. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0170 · Cited by 864
Ali, S. A., Shi, V., Maric, I., Wang, M., Stroncek, D. F., Rose, J. J., Brudno, J. N., Stetler-Stevenson, M., Feldman, S. A., Hansen, B. G., et al. (2016) · Blood · doi:10.1182/blood-2016-04-711903 · Cited by 757
Till, B. G., Jensen, M. C., Wang, J., Chen, E. Y., Wood, B. L., Greisman, H. A., Qian, X., James, S. E., Raubitschek, A., Forman, S. J., et al. (2008) · Blood · doi:10.1182/blood-2007-12-128843 · Cited by 722
Industrialization of mAb production technology: The bioprocessing industry at a crossroads
Kelley, B. (2009) · mAbs · doi:10.4161/mabs.1.5.9448 · Cited by 667
Poirot, L., Philip, B., Schiffer-Mannioui, C., Le Clerre, D., Chion-Sotinel, I., Derniame, S., Potrel, P., Bas, C., Lemaire, L., Galetto, R., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-3321 · Cited by 605
Brudno, J. N., Somerville, R. P. T., Shi, V., Rose, J. J., Halverson, D. C., Fowler, D. H., Gea-Banacloche, J. C., Pavletic, S. Z., Hickstein, D. D., Lu, T. L., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.5929 · Cited by 605
Park, J. R., DiGiusto, D. L., Slovak, M., Wright, C., Naranjo, A., Wagner, J., Meechoovet, H. B., Bautista, C., Chang, W.-C., Ostberg, J. R., et al. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300104 · Cited by 603
Zhang, C., Liu, J., Zhong, J. F., & Zhang, X. (2017) · Biomarker Research · doi:10.1186/s40364-017-0102-y · Cited by 578
Till, B. G., Jensen, M. C., Wang, J., Qian, X., Gopal, A. K., Maloney, D. G., Lindgren, C. G., Lin, Y., Pagel, J. M., Budde, L. E., et al. (2012) · Blood · doi:10.1182/blood-2011-10-387969 · Cited by 529
Jensen, M. C., Popplewell, L., Cooper, L. J., DiGiusto, D., Kalos, M., Ostberg, J. R., & Forman, S. J. (2010) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2010.03.014 · Cited by 529
Cruz, C. R. Y., Micklethwaite, K. P., Savoldo, B., Ramos, C. A., Lam, S., Ku, S., Diouf, O., Liu, E., Barrett, A. J., Ito, S., et al. (2013) · Blood · doi:10.1182/blood-2013-06-506741 · Cited by 508
Ritchie, D. S., Neeson, P. J., Khot, A., Peinert, S., Tai, T., Tainton, K., Chen, K., Shin, M., Wall, D. M., Hönemann, D., et al. (2013) · Molecular Therapy · doi:10.1038/mt.2013.154 · Cited by 443
Mitsuyasu, R. T., Anton, P. A., Deeks, S. G., Scadden, D. T., Connick, E., Downs, M. T., Bakker, A., Roberts, M. R., June, C. H., Jalali, S., et al. (2000) · Blood · doi:10.1182/blood.v96.3.785 · Cited by 425
Wang, Q.-S., Wang, Y., Lv, H.-Y., Han, Q.-W., Fan, H., Guo, B., Wang, L.-L., & Han, W.-D. (2015) · Molecular Therapy · doi:10.1038/mt.2014.164 · Cited by 418
Riddell, S. R., & Greenberg, P. D. (1990) · Journal of Immunological Methods · doi:10.1016/0022-1759(90)90210-m · Cited by 369
Deeks, S. G., Wagner, B., Anton, P. A., Mitsuyasu, R. T., Scadden, D. T., Huang, C., Macken, C., Richman, D. D., Christopherson, C., June, C. H., et al. (2002) · Molecular Therapy · doi:10.1006/mthe.2002.0611 · Cited by 324
Hollyman, D., Stefanski, J., Przybylowski, M., Bartido, S., Borquez-Ojeda, O., Taylor, C., Yeh, R., Capacio, V., Olszewska, M., Hosey, J., et al. (2009) · Journal of Immunotherapy · doi:10.1097/cji.0b013e318194a6e8 · Cited by 316
Production of lentiviral vectors
Merten, O.-W., Hebben, M., & Bovolenta, C. (2016) · Molecular Therapy - Methods & Clinical Development · doi:10.1038/mtm.2016.17 · Cited by 294
Junghans, R. P., Ma, Q., Rathore, R., Gomes, E. M., Bais, A. J., Lo, A. S. Y., Abedi, M., Davies, R. A., Cabral, H. J., Al‐Homsi, A. S., et al. (2016) · The Prostate · doi:10.1002/pros.23214 · Cited by 267
Mock, U., Nickolay, L., Philip, B., Cheung, G. W.-K., Zhan, H., Johnston, I. C. D., Kaiser, A. D., Peggs, K., Pule, M., Thrasher, A. J., et al. (2016) · Cytotherapy · doi:10.1016/j.jcyt.2016.05.009 · Cited by 237
Treatment of Advanced Leukemia in Mice with mRNA Engineered T Cells
Barrett, D. M., Zhao, Y., Liu, X., Jiang, S., Carpenito, C., Kalos, M., Carroll, R. G., June, C. H., & Grupp, S. A. (2011) · Human Gene Therapy · doi:10.1089/hum.2011.070 · Cited by 220
Towards a commercial process for the manufacture of genetically modified T cells for therapy
Kaiser, A. D., Assenmacher, M., Schröder, B., Meyer, M., Orentas, R., Bethke, U., & Dropulic, B. (2015) · Cancer Gene Therapy · doi:10.1038/cgt.2014.78 · Cited by 200
Singh, H., Figliola, M. J., Dawson, M. J., Huls, H., Olivares, S., Switzer, K., Mi, T., Maiti, S., Kebriaei, P., Lee, D. A., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-3843 · Cited by 199
Wang, Y., Zhang, W.-Y., Han, Q.-W., Liu, Y., Dai, H.-R., Guo, Y.-L., Bo, J., Fan, H., Zhang, Y., Zhang, Y.-J., et al. (2014) · Clinical Immunology · doi:10.1016/j.clim.2014.10.002 · Cited by 194
Guo, B., Chen, M., Han, Q., Hui, F., Dai, H., Zhang, W., Zhang, Y., Wang, Y., Zhu, H., & Han, W. (2016) · Journal of Cellular Immunotherapy · doi:10.1016/j.jocit.2014.11.001 · Cited by 191
CAR models: next-generation CAR modifications for enhanced T-cell function
Abate-Daga, D., & Davila, M. L. (2016) · Molecular Therapy - Oncolytics · doi:10.1038/mto.2016.14 · Cited by 187
Singh, H., Figliola, M. J., Dawson, M. J., Olivares, S., Zhang, L., Yang, G., Maiti, S., Manuri, P., Senyukov, V., Jena, B., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0064138 · Cited by 170
Dai, H., Zhang, W., Li, X., Han, Q., Guo, Y., Zhang, Y., Wang, Y., Wang, C., Shi, F., Zhang, Y., et al. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1027469 · Cited by 166
Vera, J. F., Brenner, L. J., Gerdemann, U., Ngo, M. C., Sili, U., Liu, H., Wilson, J., Dotti, G., Heslop, H. E., Leen, A. M., et al. (2010) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181c0c3cb · Cited by 165
Gogol-Döring, A., Ammar, I., Gupta, S., Bunse, M., Miskey, C., Chen, W., Uckert, W., Schulz, T. F., Izsvák, Z., & Ivics, Z. (2016) · Molecular Therapy · doi:10.1038/mt.2016.11 · Cited by 160
Levine, B. L. (2015) · Cancer Gene Therapy · doi:10.1038/cgt.2015.5 · Cited by 128
Simplified process for the production of anti–CD19-CAR–engineered T cells
Tumaini, B., Lee, D. W., Lin, T. L., Castiello, L., Stroncek, D. F., Mackall, C. L., Wayne, A. S., & Sabatino, M. (2013) · Cytotherapy · doi:10.1016/j.jcyt.2013.06.003 · Cited by 123
Inclusion of an IgG1-Fc spacer abrogates efficacy of CD19 CAR T cells in a xenograft mouse model
Almåsbak, H., Walseng, E., Kristian, A., Myhre, M. R., Inderberg, E. M., Munthe, L. A., Andersen, J. T., WANG, M. Y., Kvalheim, G., Gaudernack, G., et al. (2015) · Gene Therapy · doi:10.1038/gt.2015.4 · Cited by 117
Development of CAR T cells designed to improve antitumor efficacy and safety
Jaspers, J. E., & Brentjens, R. J. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.03.012 · Cited by 112
Construction of stable packaging cell lines for clinical lentiviral vector production
Sanber, K. S., Knight, S. B., Stephen, S. L., Bailey, R., Escors, D., Minshull, J., Santilli, G., Thrasher, A. J., Collins, M. K., & Takeuchi, Y. (2015) · Scientific Reports · doi:10.1038/srep09021 · Cited by 108
Modulation of Blood Cell Activation by Four Commonly Used Anticoagulants
Engstad, C. S., Gutteberg, T. J., & Østerud, B. (1997) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1656035 · Cited by 102
Challenges and opportunities of allogeneic donor-derived CAR T cells
Yang, Y., Jacoby, E., & Fry, T. J. (2015) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000181 · Cited by 101
Manufacture of tumor- and virus-specific T lymphocytes for adoptive cell therapies
Wang, X., & Rivière, I. (2015) · Cancer Gene Therapy · doi:10.1038/cgt.2014.81 · Cited by 100
Somerville, R. P. T., Devillier, L., Parkhurst, M. R., Rosenberg, S. A., & Dudley, M. E. (2012) · Journal of Translational Medicine · doi:10.1186/1479-5876-10-69 · Cited by 97
Barrett, D. M., Singh, N., Liu, X., Jiang, S., June, C. H., Grupp, S. A., & Zhao, Y. (2014) · Cytotherapy · doi:10.1016/j.jcyt.2013.10.013 · Cited by 96
Ramanayake, S., Bilmon, I., Bishop, D. C., Dubosq, M., Blyth, E., Clancy, L. E., Gottlieb, D. J., & Micklethwaite, K. P. (2015) · Cytotherapy · doi:10.1016/j.jcyt.2015.05.013 · Cited by 92
Current status of chimeric antigen receptor therapy for haematological malignancies
Maude, S. L., & Barrett, D. M. (2015) · British Journal of Haematology · doi:10.1111/bjh.13792 · Cited by 88
CAR-T Cell Therapies From the Transfusion Medicine Perspective
Fesnak, A. D., Lin, C., Siegel, D. L., & Maus, M. V. (2016) · Transfusion Medicine Reviews · doi:10.1016/j.tmrv.2016.03.001 · Cited by 87
Singh, H., Moyes, J. S. E., Huls, M. H., & Cooper, L. J. N. (2015) · Cancer Gene Therapy · doi:10.1038/cgt.2014.69 · Cited by 77
Casati, A., Varghaei-Nahvi, A., Feldman, S. A., Assenmacher, M., Rosenberg, S. A., Dudley, M. E., & Scheffold, A. (2013) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-013-1459-x · Cited by 73
CD 19 chimeric antigen receptor T cell therapy for haematological malignancies
Ghorashian, S., Pulè, M. A., & Amrolia, P. J. (2015) · British Journal of Haematology · doi:10.1111/bjh.13340 · Cited by 63
Self-citationInclusion of Strep-tag II in design of antigen receptors for T-cell immunotherapy
Liu, L., Sommermeyer, D., Cabanov, A., Kosasih, P. L., Hill, T. J., & Riddell, S. R. (2016) · Nature Biotechnology · doi:10.1038/nbt.3461 · Cited by 63
Gardner, R., Finney, O. C., Smithers, H. M., Leger, K. J., Annesley, C., Summers, C. N., Brown, C., Mgebroff, S., Lindgren, C. G., Spratt, K., et al. (2016) · Blood · doi:10.1182/blood.v128.22.219.219 · Cited by 40
McFarland, D. C., Zhang, C., Thomas, H. C., & Ratliff, T. L. (2006) · Cytometry Part A · doi:10.1002/cyto.a.20207 · Cited by 35
Manufacturing genetically modified T cells for clinical trials
Gee, A. P. (2015) · Cancer Gene Therapy · doi:10.1038/cgt.2014.71 · Cited by 34
Kebriaei, P., Huls, H. M., Singh, H., Olivares, S., Figliola, M. J., Maiti, S. N., Su, S., Kumar, P. R., Jena, B., Forget, M., et al. (2014) · Blood · doi:10.1182/blood.v124.21.311.311 · Cited by 23
Detection of Replication Competent Lentivirus Using a qPCR Assay for VSV-G
Skrdlant, L. M., Armstrong, R. J., Keidaisch, B. M., Lorente, M. F., & DiGiusto, D. L. (2017) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2017.09.001 · Cited by 23
Kebriaei, P., Ciurea, S. O., Huls, M. H., Singh, H., Olivares, S., Su, S., Figliola, M. J., Kumar, P. R., Jena, B., Forget, M., et al. (2015) · Blood · doi:10.1182/blood.v126.23.862.862 · Cited by 15
Kochenderfer, J. N., Dudley, M. E., Carpenter, R. O., Kassim, S. H., Rose, J. J., Telford, W. G., Hakim, F. T., Halverson, D. C., Fowler, D. H., Hardy, N. M., et al. (2013) · Blood · doi:10.1182/blood.v122.21.151.151 · Cited by 10
Cited by
A guide to cancer immunotherapy: from T cell basic science to clinical practice
Waldman, A. D., Fritz, J. M., & Lenardo, M. J. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-0306-5 · Cited by 4,154
Mechanisms of resistance to CAR T cell therapy
Shah, N. N., & Fry, T. J. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0184-6 · Cited by 959
Ionizable Lipid Nanoparticle-Mediated mRNA Delivery for Human CAR T Cell Engineering
Billingsley, M. M., Singh, N., Ravikumar, P., Zhang, R., June, C. H., & Mitchell, M. J. (2020) · Nano Letters · doi:10.1021/acs.nanolett.9b04246 · Cited by 636
CRISPR-Cas9: A Preclinical and Clinical Perspective for the Treatment of Human Diseases
Sharma, G., Sharma, A. R., Bhattacharya, M., Lee, S.-S., & Chakraborty, C. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2020.09.028 · Cited by 283
Billingsley, M. M., Gong, N., Mukalel, A. J., Thatte, A. S., El‐Mayta, R., Patel, S. K., Metzloff, A. E., Swingle, K. L., Han, X., Xue, L., et al. (2024) · Small · doi:10.1002/smll.202304378 · Cited by 268
Metadata
- Authors
- Vormittag, P., Gunn, R., Ghorashian, S., & Veraitch, F. S.
- Venue
- Current Opinion in Biotechnology
- Publisher
- Elsevier BV
- Published
- 2018-10
- Volume
- 53
- Pages
- 164-181
- ISSN
- 0958-1669 (ISSN-L)
- OpenAlex
- W2790491347
- Cited by
- 383
- References
- 82
- FWCI
- 4.29
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.